Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) ...

CitiusTech's John Edward discusses how AI can transform healthcare despite imperfect data, exploring Agentic AI, data quality ...